GlassScriptPhysician profile
Andrew Lombardi
NPI 1164119095
$3,651.66
in general payments reported to CMS, 2019-2025
26 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $598 · 2024: $1,571 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,651.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $363.78 | 2024-2025 | Terlivaz, Acthar |
| Amgen INC. | $297.97 | 2023-2025 | Krystexxa, Epogen, Parsabiv |
| Glaxosmithkline, LLC. | $272.09 | 2023-2025 | Jesduvroq, Benlysta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $258.09 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.68 | 2023-2025 | Jardiance |
| Abbott Laboratories | $246.36 | 2024 | Freestyle Libre 3, Cardiomems |
| Novo Nordisk INC | $231.43 | 2024-2025 | Wegovy, Ozempic |
| Boston Scientific Corporation | $227.92 | 2023-2025 | Watchman Access System |
| Corcept Therapeutics | $213.63 | 2024-2025 | Korlym |
| Abiomed | $200.09 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $176.21 | 2024-2025 | Airsupra, Farxiga |
| Axonics, INC. | $118.06 | 2024 | Axonics, Bulkamid |
| Actelion Pharmaceuticals US, INC. | $117.68 | 2024 | Uptravi, Opsumit |
| Neurocrine Biosciences, INC. | $116.43 | 2025 | |
| Insmed, INC. | $105.30 | 2025 | Arikayce |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $84.02 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $59.19 | 2023-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $53.30 | 2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $51.90 | 2023 | Velphoro |
| Ardelyx, INC. | $47.48 | 2024-2025 | Ibsrela |
| Renalytix Ai, INC. | $45.08 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Apellis Pharmaceuticals, INC. | $29.77 | 2025 | Empaveli |
| Akebia Therapeutics INC | $29.45 | 2025 | Vafseo |
| Opko Pharmaceuticals, LLC | $22.41 | 2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $20.67 | 2024 | |
| Travere Therapeutics, INC. | $5.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lombardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.